TABLE 3.
Simulated patient characteristics in the finally generated combined dataset (N = 26,173).
| Continuous data | Value [(mean ± SD) or median (min–max)] | Categorical data | Distribution [n (%)] |
|---|---|---|---|
| (mg/L) | 73.7 ± 37.2 | Male | 7,237 (27.65%) |
| BW (kg) | 64.3 ± 12.4 | CYP2C19*1/*1 | 8,358 (31.93%) |
| ALB (g/L) | 37.9 ± 5.6 | CYP2C19*2 and/or *3 variants | 6,151 (23.50%) |
| Daily Dose (mg) | 900 (125–3,600) | Co-administered CBZ | 1,636 (6.25%) |
| Single Dose (mg) | 450 (125–900) | Co-administered PHT | 1,529 (5.84%) |
| (h) | 5.57 (0–24) | Co-administered PB | 1,421 (5.43%) |
| (h) | 12 (6–24) | Co-administered CBZ + PHT | 1,854 (7.08%) |
| Co-administered CBZ + PB | 1,735 (6.63%) | ||
| Co-administered PHT + PB | 1,652 (6.31%) | ||
| Co-administered CBZ + PHT + PB | 1,837 (7.02%) |
Note: Css denotes the steady-state concentrations of VPA, t denotes the blood sampling time, and τ denotes the dosing interval.